U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07203391) titled 'Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis' on Sept. 21.
Brief Summary: This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Uveal Melanoma, Metastatic
Intervention:
DRUG: roginolisib
Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)
Recruitment Status: RECRUITING
Sponsor: St Vincent's Hospital, Sydney
Information provided by (Responsible Party): Anthony Joshua, FRACP, St Vincent's Hospital, Sydney
Published by HT Digital Content Services with permission from Health Daily...